DBVT News and Press, DBV Technologies S.A. From 11/09/22

Montrouge, France, November 9, 2022 DB V Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that ...

DBV Technologies S.A. (DBVT) Q3 2022 Earnings Conference Call November 04, 2022 5:00 PM ET Company Participants Anne Pollak – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Confere...

DBV Technologies press release ( NASDAQ: DBVT ): Q3 GAAP EPS of -$0.18. Revenue of $2.07M (+56.8% Y/Y). For further details see: DBV Technologies GAAP EPS of -$0.18, revenue of $2.07M

Montrouge, France, November 3, 2022 DBV Technologies Reports Third Quarter Financial Results and Business Update DBV closes Q3 with a cash balance of $213M DBV continues to practice budget discipline measures; cash used in operating activities decreased more than 35% b...

Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euron...

Montrouge, France, October 3, 2022 DBV Technologies Announ ces Appointment of New Chair of its Audit Committee and A ppointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

French biotech DBV Technologies ( NASDAQ: DBVT ) on Wednesday said the U.S. FDA had put a partial clinical hold on its phase 3 clinical study evaluating its Viaskin Peanut patch for the treatment of peanut allergy in children aged 4 through 7. The FDA specified certain cha...

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it recei...